Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FRK_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FRK_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FRK_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FRK_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FRK | SNV | Missense_Mutation | rs374511452 | c.1207N>A | p.Glu403Lys | p.E403K | P42685 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FRK | SNV | Missense_Mutation | | c.1298N>A | p.Pro433His | p.P433H | P42685 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FRK | SNV | Missense_Mutation | | c.842T>C | p.Met281Thr | p.M281T | P42685 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FRK | SNV | Missense_Mutation | novel | c.965N>T | p.Thr322Ile | p.T322I | P42685 | protein_coding | deleterious(0.03) | benign(0) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
FRK | SNV | Missense_Mutation | novel | c.521N>A | p.Gly174Glu | p.G174E | P42685 | protein_coding | deleterious(0.03) | benign(0.054) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
FRK | SNV | Missense_Mutation | novel | c.404A>G | p.Asn135Ser | p.N135S | P42685 | protein_coding | deleterious(0.03) | possibly_damaging(0.817) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FRK | insertion | In_Frame_Ins | novel | c.27_28insCATTTT | p.Trp9_Glu10insHisPhe | p.W9_E10insHF | P42685 | protein_coding | | | TCGA-A5-A0GV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FRK | insertion | Nonsense_Mutation | novel | c.26_27insTAAAATAACTCATGCCTCACTTTAGCAATAAAATT | p.Trp9CysfsTer9 | p.W9Cfs*9 | P42685 | protein_coding | | | TCGA-A5-A0GV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FRK | SNV | Missense_Mutation | novel | c.916N>T | p.Thr306Ser | p.T306S | P42685 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CC-A5UD-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
FRK | SNV | Missense_Mutation | novel | c.89N>G | p.Glu30Gly | p.E30G | P42685 | protein_coding | tolerated(0.3) | benign(0) | TCGA-XR-A8TG-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | | TAMATINIB | R-406 | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | NINTEDANIB | NINTEDANIB | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | | RG-1530 | RG-1530 | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | | GEFITINIB | GEFITINIB | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | | ALISERTIB | ALISERTIB | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | CHEMBL1421 | DASATINIB | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | CHEMBL1980297 | ILORASERTIB | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | | IMATINIB | IMATINIB | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | inhibitor | CHEMBL3545085 | XL-228 | |
2444 | FRK | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, ENZYME | | ILORASERTIB | ILORASERTIB | |